Fortress Biotech Inc expected to post a loss of 75 cents a share - Earnings Preview

Fortress Biotech

21/03/2025 12:09

Fortress Biotech Inc FBIO.OQ FBIO.O is expected to show a fall in quarterly revenue when it reports  results on March 24 (estimated) for the period ending December 31 2024

The Bay Harbor Islands Florida-based  company is expected to report a 18.3% decrease in revenue to $16.297 million from $19.95 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Fortress Biotech Inc is for a loss of 75 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Fortress Biotech Inc is $16.00​, above​ its last closing price of $1.70. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.59
-0.59
-0.76
Missed
-27.7
Jun. 30 2024
-1.14
-1.22
-0.73
Beat
40.3
Mar. 31 2024
-1.69
-1.73
-1.03
Beat
40.5​
Dec. 31 2023
-1.67
-1.97
-1.28
Beat
34.9
​​Sep. 30 2023
-3.12
-3.21
-0.94
Beat
70.7
Jun. 30 2023
-3.31
-3.41
-3.60
Missed
-5.5​
Mar. 31 2023
-3.38
-3.00
-3.15
Missed
-5
Dec. 31 2022
-3.43
-3.37
-4.46
Missed
-32.2

This summary was machine generated March 21 at 12:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)